Digital Productivity
Organizations
Conferences
Info & Opinion
May 16, 2008
A report from the Clinical Trials Congress about risk. One message: start a regulatory conversation early. And consult your preclinical team.
A presentation from the 2008 Clinical Trials Congress on how to think about improving strategic relationships between sponsors.
Two leading firms, Tessella and United Biosource, discuss the perception that regulators are trying to slow down the adoption of adaptive designs.
With impressive numbers, Pfizer’s Mike Collins talked about how the company is streamlining its clinical trial process.
Should the life sciences be in a self-congratulatory mood about moving away from paper and toward electronic data capture (EDC)? Nope. For Ron Waife, president of Waife & Associates, it may be premature to ask John Williams to compose a symphony to celebrate the shift. Waife is simply not sure… more...
There are a plethora of small conferences in our industry. They address topics as diverse as electronic patient-reported outcomes, (ePRO), eclinical technology, regulatory affairs, patient recruitment and outsourcing. These meetings can be quite broad (the Clinical Trials Congress) or sharply focused (The Advanced Import Compliance Forum). Many of these conferences… more...
With the adoption of any new technology—from coal to lasers—lofty expectations are slowly eroded by the day-to-day reality of the technology in actual use. In the clinical trial landscape, the tool of the hour is electronic data capture (EDC). Is it helping? Is it making a difference? Jason Ridderikhoff, regional… more...
Some industries simply move jobs to India. Simple. Done. In pharma, the situation is more complex. John Balian, senior VP of global pharmacovigilance and epidemiology at Bristol-Myers Squibb (BMS) told the huge 2008 “Partnerships With CROs” conference in Las Vegas this week that his company has also had a more… more...
The 2008 Clinical Trials Congress had deep tracks of sessions around patient recruitment and trial budgeting. The familiar paradox is that as more sponsors seek more patients, patients become even more scarce. But now that conventional wisdom seems to be upside down. Instead of the familiar refrain of more patients,… more...
Talk about a rock and a hard place. Once drugs reach the market, or as a condition prior to approval, the industry’s handling of risk is caught between the needs of regulators, shareholders and public. At the 2008 Clinical Trials Congress, held in Orlando, there were signs that the burdens… more...
Jargon and catch phrases grate on our ears like fingernails on a blackboard. Plain old English is enough. Important-sounding buzzwords are designed to conceal the underlying ideas, not illuminate them. But in the case of “alliance management,” a phrase that sounds new to our weary ears, we may have to… more...